Even small deviations from recommended dosing times can delay absorption or completely block the intended effect of ...
Romosozumab was not associated with increased cardiovascular risks among patients with osteoporosis when compared with bisphosphonate use. Romosozumab does not appear to significantly increase the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback